A multinational team of researchers has discovered that over 20% of adults with a normal BMI range experience levels of ...

Once-weekly semaglutide 2.4 mg conferred a greater reduction in major adverse cardiovascular events than placebo, regardless ...

More work needs to be done to tease out the mechanisms by which GLP-1 RAs lower the risk of MACE, researchers say.

Semaglutide can reduce cardiac event risk regardless of a patient’s starting body fat or weight loss during treatment, ...

According to new research, a thick neck can be an accurate predictor of cardiovascular risk, as well as indicate type 2 ...

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular ...

Even when weight doesn’t drop much, the obesity-medication semaglutide still offers major heart-protection, research shows.

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

Two studies demonstrate that a large proportion of the population has visceral adiposity even at BMIs below the obesity ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.